Duchenne community campaigns for givinostat

The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July,...
DMD Care UK national meeting drives improved care

DMD Care UK national meeting drives improved care

Pictured: DRF director of operations Sheli Rodney (second from right) with fellow members of the Psychosocial Working Group: disability and education specialist Dr Janet Hoskin, DMD Care UK manager Cathy Turner, Pathfinders Neuromuscular Alliance trustee Benjamin...

NICE approves DRF-funded treatment for Duchenne

New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...

John Walton Muscular Dystrophy Research Centre marks 10 years

We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle. The late Lord John Walton was a pioneering neurologist who made an enormous impact on muscular dystrophy diagnosis and treatment. The...

DMD Care UK explores next steps for patient care

On 29th February, Rare Disease Day, we were pleased to be part of the 2024 national meeting for DMD Care UK. More than 130 clinicians and 25 patient representatives are now involved in DMD Care UK, giving their time and expertise across no fewer than 13 working groups...

DMD Care UK launches new respiratory guidance

We are pleased to share that DMD Care UK’s new respiratory guidance has been endorsed by the British Thoracic Society and published in Thorax, an international peer-reviewed medical journal with a respiratory focus. It is published by the BMJ Group on behalf of...

Vamorolone approved in the EU

The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...

Vamorolone approved in the US

The US FDA (Food and Drug Administration) has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree and is expected to be available in the US in early 2024. This...

See the smart suit that is changing children’s lives

On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart...